| Page 59 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes

Author(s): 
Qing Zhang, Mintallah Haider, Najla H Al Ali, Jeffrey E Lancet, Pearlie K Epling-Burnette, Alan F List, Eric Padron, Rami S Komrokji
Primary Author: 
Qing Zhang
Journal Title: 
Clinical Lymphoma , Myeloma & Leukemia
Original Publication Date: 
Jun 2020

Background: Immunosuppressive therapy (IST) yields durable hematologic improvement (HI) in a subset of patients with lower-risk myelodysplastic syndrome (MDS). Age,

Bone Marrow Disease(s): 

To Target the Untargetable: Elucidation of Synergy of APR-246 and Azacitidine in TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia

Author(s): 
David A Sallman
Primary Author: 
David A Sallman
Journal Title: 
Haematologica
Original Publication Date: 
Jun 2020

Rigosertib in Combination With Azacitidine in Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia: Results of a Phase 1 Study

Author(s): 
Shyamala C Navada, Guillermo Garcia-Manero, Rosalie OdchimarReissig, Naveen Pemmaraju, Yesid Alvarado, Maro N Ohanian, Rosmy B John, Erin P Demakos, Patrick S Zbyszewski, Manoj Maniar, Richard C Woodman, Steven M Fruchtman, Lewis R Silverman
Primary Author: 
Shyamala C Navada
Journal Title: 
Leukemia Research
Original Publication Date: 
Jul 2020

Phase 1 results from a Phase 1/2 study comprise 18 patients with

Iron Overload Alters the Energy Metabolism in Patients With Myelodysplastic Syndromes: Results From the Multicenter FISM BIOFER Study

Author(s): 
Daniela Cilloni, Silvia Ravera, Chiara Calabrese, Valentina Gaidano, Pasquale Niscola, Enrico Balleari, Daniela Gallo, Jessica Petiti, Elisabetta Signorino, Valentina Rosso, Cristina Panuzzo, Federica Sabatini, Giacomo Andreani
Primary Author: 
Daniela Cilloni
Journal Title: 
Scientific Reports
Original Publication Date: 
Jun 2020

Bone Marrow Disease(s): 

High Serum Ferritin Levels in Newly Diagnosed Patients With Myelodysplastic Syndromes Are Associated With Greater Symptom Severity

Author(s): 
Giovanni Caocci, Marco Vignetti, Andrea Patriarca, Massimo Breccia, Uwe Platzbecker, Giuseppe A Palumbo, Reinhard Stauder, Francesco Cottone, Duska Petranovic, Maria Teresa Voso, Agostino Tafuri, Rosangela Invernizzi, Jo Caers
Primary Author: 
Giovanni Caocci
Journal Title: 
International Journal of Hematology
Original Publication Date: 
Jun 2020

We examined the association between serum

Bone Marrow Disease(s): 

Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients With Myelodysplastic Syndromes: Results of a Large Web-Based Survey

Author(s): 
Alexander B Pine, Nora Chokr, Maximilian Stahl, David P Steensma, Mikkael A Sekeres, Mark R Litzow, Selina M Luger, Richard M Stone, Peter L Greenberg, Rafael Bejar, Jan P Bewersdorf, Steven D Gore, Amer M Zeidan
Primary Author: 
Alexander B Pine
Journal Title: 
Leukemia & Lymphoma
Original Publication Date: 
Jun 2020

Next-generation sequencing (NGS) is increasingly employed for diagnosis, risk stratification, and management of patients with myelodysplastic syndrome (MDS). We aimed to describe beliefs and practice patterns among providers who treat MDS patients with respect to the utility of NGS in diagnosis, risk stratification, prognosis, and treatment decisions at various points along the disease trajectory, response assessment, and development of institutional guidelines for MDS-specific molecular profiling.

Bone Marrow Disease(s): 

Venetoclax and Hypomethylating Agents (HMAs) Induce High Response Rates in MDS, Including Patients After HMA Therapy Failure

Author(s): 
Brian J Ball, Christopher A Famulare, Eytan M Stein, Martin S Tallman, Andriy Derkach, Mikhail Roshal, Saar I Gill, Benjamin M Manning
Primary Author: 
Brian J Ball
Journal Title: 
Blood Advances
Original Publication Date: 
Jul 2020

Hypomethylating agents (HMAs) are the current standard of care in high-risk

Bone Marrow Disease(s): 

Where There's Smoke, There's Fire: Inflammation Drives MDS

Author(s): 
Gandhar K Datar, Margaret A Goodell
Primary Author: 
Gandhar K Datar
Journal Title: 
Trends in immunology
Original Publication Date: 
Jul 2020

Chronic inflammation has been implicated in myelodysplastic syndrome (MDS); however, its role in disease progression is unclear. In a new study by Muto et al., MDS

Bone Marrow Disease(s):